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leta-Blockers in Elderly
atients With Heart Failure
eady for Prime Time?
e congratulate Hernandez et al. (1) for this important paper on the
rognostic impact of beta-blockers in elderly community patients with
eart failure (HF). The current evidence suggests beta-blocker use
eyond any doubt but in rather limited patient populations (2).
arge-scale randomized trials primarily included white male subjects
ith left ventricular systolic dysfunction due to ischemic heart disease,
hereas the guidance in elderly patients or those with preserved left
entricular systolic function is less robust (2,3). Hence, guidelines
mplementation in eligible patients is unsatisfactory (4) and largely
riven by patient age and left ventricular function (5).
Although beta-blockers have gained an indisputable status in patients
ithHF, it remains unclear whether we should pursue target doses in the
lderly population or whether clinical benefit could be gained with lower
oses. Previous epidemiological studies demonstrated failure to reach
uideline beta-blocker dose in more than one-half of real-world patients
ithHF (6), even in thosemanaged by cardiologists (7).According to the
urrent report of Hernandez et al. (1) and previous reports (8), it is
lausible not to withhold beta-blockers when discharging elderly patients
ith HF and left ventricular systolic dysfunction. In this context, current
uropean Society of Cardiology guidelines (2) suggest less-tight up-
itration than dictated by major trials. Whether up-titration of beta-
lockers per landmark trials protocol is feasible and safe in elderly patients
ith HF has never been tested head-to-head, but we need to know this
o make clinical use of the results shown by Hernandez et al. (1). The
IBIS-ELD (Cardiac Insufficiency Bisoprolol Study in Elderly) trial
ims to fill in this gap (9). Patients with HF and left ventricular
ysfunction (either systolic or diastolic or both) ages 65 years were
andomized in a double-blind, double-dummy manner to bisoprolol or
arvedilol to test tolerability, safety, and feasibility of a 2-week escalating
ose titration scheme to target dose. Whatever the results of the
IBIS-ELD trial, the clinical message by Hernandez et al. (1) should be
nterpreted and implemented for patient benefit.Nonetheless, for optimal
are of patients with HF, we still need to know how to use beta-blockers
ost effectively. The CIBIS-ELD trial, which completed 3-month
ollow-up late in 2008, is expected to report shortly and could importantly
nfluence our clinical practice.
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tainless Steel Stents and
agnetic Resonance Imaging
ooking Into a Black Hole
e commend Thanopoulos et al. (1) for their complete follow up of
6 adult patients undergoing aortic stenting for both native and
ecurrent coarctation of the aorta (CoA). Although endovascular
tenting is the treatment of choice in many centers for CoA in older
hildren and adults, there have been no complete longer-term
ollow-up studies evaluating stent durability, stenosis, and aneurysm
ormation, and this study adds some reassuring data to the published
eports. However, we have concerns about the use of magnetic
esonance imaging (MRI) after implantation of stainless steel stents
Palmaz stents, Johnson and Johnson International Systems, Warren,
ew Jersey) to evaluate stent integrity and effects on the aortic wall.
here have been numerous reports demonstrating almost complete
oss of signal with stainless steel stents both ex vivo and in vivo when
maging with magnetic resonance, leading to significant image arte-
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December 1, 2009:2202–4acts and obscuring of the vessel lumen (2–4). These artefacts are
ost problematic with steady state free precession (SSFP) and
adolinium angiography. Typical metallic stent artifact on MRI
auses signal dropout due to magnetic susceptibility and radiofre-
uency shielding. Magnetic susceptibility scrambles the phases of
ndividual spins leading to signal void, which is almost complete with
tainless steel—particularly when compared with other alloys such as
itinol and platinum (2). Radiofrequency shielding refers to current
nduced in the stent wall that opposes the original magnetic field and
eads to reduction in overall signal. This current increases with the
esonance frequency, and thus shielding becomes more pronounced
ith high field strengths used in clinical imaging. Thus, MRI is not
quipped to identify in-stent stenosis or aneurysm formation, and
ndeed lack of signal might give falsely reassuring appearances within
he vessel lumen.
The authors used multislice computed tomography at the end of
heir 5-year follow-up, and we feel this imaging modality is not
usceptible to the same artefact and signal loss as MRI (5). Although
he authors did not demonstrate aortic aneurysm formation in their
eries, other larger albeit less complete series have demonstrated
neurysm formation of up to 9% (6), and this might have been missed
ith MRI, leading to potentially serious consequences. Indeed most
neurysm formation secondary to stenting is likely to occur soon after
he procedure, and thus a 5-year delay for accurate imagingmight lead
o unnecessary patient risk. The magnetic resonance scanning, al-
hough safe, is expensive; thus to ensure both clinically relevant and
ost-effective follow-up of patients undergoing aortic stenting in the
etting of CoA, we suggest early (3 months) post-procedural com-
uterized tomography imaging. Some might argue a significant
adiation load accompanies this form of imaging; however, with
imited scan length, nonelectrocardiogram gating, and use of tube
odulation to reduce unnecessary current, it is possible to ensure that
his is kept to a minimum.
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eply
e fully agree with the comments of Dr. Kenny and colleagues.
ultislice computed tomography (MSCT) is currently the
oninvasive imaging modality of choice for the evaluation of
atients with coarctation of the aorta (CoA) after stent implan-
ation. Indeed, this technique provides detailed 3-dimensional
natomic images not only of the aorta but also of the coronary
rteries, which is of great importance for adult patients with
oA. In addition, accurate measurements of the aortic diame-
ers at the stented segment can be obtained with this imaging
odality. A major limitation of this technique is the significant
adiation exposure—which, however, will be lowered in the
ot-so-far future with the newer 256 MSCT devices.
Magnetic resonance imaging (MRI) is of limited value in
oA after stent implantation, because the stent-related “shield-
ng” artifacts prevent detailed evaluation of the aorta within the
tented aortic area. In our study (1), MRI angiography was used
or patient evaluation before the intervention and at follow-up
or the evaluation of the intervention result when MSCT was
ot available and also for the assessment of the brain circulation
circle of Willis). We currently use MSCT to identify stent
ractures and in-stent restenosis and to evaluate the effects of
ntervention on aortic wall at 1 month and 2 and 5 years after
tent implantation for adult CoA.
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larification and
orrection About the
esign and Implementation
f the PROSPECT Trial
n his commentary in the May 26, 2009, issue of the Journal,
anderson (1) makes assertions about the design and implementation
